RayKnowChina Research Map
Shortlist

RecruitingBreast cancerN/A

Registered title, quoted from ClinicalTrials.gov

Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 12 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 13

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  2. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  3. Study siteGuizhou Provincial People's Hospital贵州省人民医院GuiyangHospital page
  4. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  5. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  6. Study siteNingbo Medical Center Lihuili Hospital宁波市医疗中心李惠利医院NingboHospital page
  7. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  8. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  9. Study siteShanghai General Hospital上海市第一人民医院ShanghaiHospital page
  10. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  11. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  12. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  13. Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07469267, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: women only

    Registered eligibility fields

  2. Have one or two macrometastases (>2 mm) at sentinel lymph node biopsy,and without further axillary lymph node dissection;

    Inclusion criterion 5

  3. Clinical stage T4 or IV (metastatic) breast cancer, or presence of regional metastases before surgery;

    Exclusion criterion 2

  4. Radiation therapy must begin no later than 12 weeks after the last dose of adjuvant chemotherapy or the last breast cancer surgery if no adjuvant chemotherapy;

    Inclusion criterion 8

  5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;

    Inclusion criterion 6

  6. Current pregnancy and/or lactation;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07469267, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female ≥ 18 years of age;
  • Newly diagnosed primary invasive breast cancer;
  • Clinically stage T1-3N0M0;
  • Patients received surgery as first treatment,and have undergone breast conserving-surgery or mastectomy (with or without breast reconstruction) with negative margins;
  • Have one or two macrometastases (>2 mm) at sentinel lymph node biopsy,and without further axillary lymph node dissection;
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
  • Will receive endocrine therapy for at least 5 years for estrogen receptor (ER) and/or progesterone receptor (PR) positive patients; will receive anti-HER2 (human epidermal growth factor receptor 2) therapy for 1 year for HER2 positive patients;
  • Radiation therapy must begin no later than 12 weeks after the last dose of adjuvant chemotherapy or the last breast cancer surgery if no adjuvant chemotherapy;
  • Patients have adequate organ function;
  • Acquirement of informed consent.

Exclusion Criteria:

  • Patients have received neoadjuvant systemic therapy;
  • Clinical stage T4 or IV (metastatic) breast cancer, or presence of regional metastases before surgery;
  • History of any prior ipsilateral or contralateral invasive breast cancer, history of other malignancies except for appropriately treated skin basal cell carcinoma and cervical carcinoma in situ;
  • History of previous radiotherapy towards the ipsilateral chest/lymph nodes.
  • The ipsilateral axillary lymph node dissection or other previous axillary surgery;
  • Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, or psychiatric disease), inability to tolerate radiotherapy or systemic therapy if indicated;
  • Current pregnancy and/or lactation;
  • Inability or unwillingness to comply with protocol requirements.

Quoted from ClinicalTrials.gov, NCT07469267, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07469267, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07469267